Journal
BJU INTERNATIONAL
Volume 103, Issue 4, Pages 441-445Publisher
WILEY-BLACKWELL PUBLISHING, INC
DOI: 10.1111/j.1464-410X.2008.08280.x
Keywords
PSA; PCA3; prostate cancer; biopsy; decision
Categories
Ask authors/readers for more resources
The decision to take a prostate biopsy is traditionally guided by a digital rectal examination and measurement of serum total prostate-specific antigen (tPSA). However, both techniques are subject to inherent weaknesses. The prostate cancer gene 3 (PCA3), a gene-based marker, specific for prostate cancer, supplements the predictive power of tPSA to improve diagnosis of disease. Including this new marker in the standard of care for men at risk of prostate cancer should be considered, as it presents marked potential for better decision making for a prostate biopsy and for improving overall patient care.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available